Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

116 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.
Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM. Papp KA, et al. Among authors: yu ap. Clin Drug Investig. 2011;31(1):51-60. doi: 10.2165/11539360-000000000-00000. Clin Drug Investig. 2011. PMID: 20932070
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Kimball AB, et al. Among authors: yu ap. Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21110526 Clinical Trial.
116 results